Jazz Pharmaceuticals
Irish tax-registered pharmaceutical corporation
JAZZ Nasdaq
ISIN IE00B4Q5ZN47 SEC CIK 1232524
Follow Jazz Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$1.2B
+10.4% vs same quarter last year
Net income
−$483.4M
−292.3% vs same quarter last year
EPS, diluted
−$7.48
−283.3% vs same quarter last year
Operating cash flow
$506.1M
+6.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $4.3B | −$356.1M |
| FY24 | $4.1B | $560.1M |
| FY23 | $3.8B | $414.8M |
| FY22 | $3.7B | −$224.1M |
| FY21 | $3.1B | −$329.7M |
| FY20 | $2.4B | $238.6M |
| FY19 | $2.2B | $523.4M |
| FY18 | $1.9B | $447.1M |
| FY17 | $1.6B | $487.8M |
| FY16 | $1.5B | $396.8M |
| FY15 | $1.3B | $329.5M |
| FY14 | $1.2B | $58.4M |
| FY13 | $872.4M | $216.3M |
| FY12 | $586M | $288.6M |
| FY11 | $272.3M | $125M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −10.1% | −8.3% |
| FY24 | 17.6% | 13.8% |
| FY23 | 15.1% | 10.8% |
| FY22 | −1.8% | −6.1% |
| FY21 | 5.5% | −10.7% |
| FY20 | 16% | 10.1% |
| FY19 | 24.6% | 24.2% |
| FY18 | 32.5% | 23.6% |
| FY17 | 32.7% | 30.1% |
| FY16 | 39.8% | 26.7% |
| FY15 | 38.4% | 24.9% |
| FY14 | 16.7% | 5% |
| FY13 | 39% | 24.8% |
| FY12 | 33.8% | 49.2% |
| FY11 | 46.9% | 45.9% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $1.3B |
| FY24 | $1.4B |
| FY23 | $1.1B |
| FY22 | $1.2B |
| FY21 | $750.9M |
| FY20 | $884.6M |
| FY19 | $736.3M |
| FY18 | $778.5M |
| FY17 | $664.1M |
| FY16 | $582.7M |
| FY15 | $496M |
| FY14 | $371.3M |
| FY13 | $278.5M |
| FY12 | $243.8M |
| FY11 | $150.3M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $125M |
| FY24 | $311.4M |
| FY23 | $269.8M |
| FY22 | $54K |
| FY21 | $0 |
| FY20 | $146.5M |
| FY19 | $301.5M |
| FY18 | $523.7M |
| FY17 | $98.8M |
| FY16 | $278.3M |
| FY15 | $61.6M |
| FY14 | $42.2M |
| FY13 | $136.5M |
| FY12 | $0 |
| FY11 | $0 |
- Jazz Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Jazz Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −8.3% | −30.6% |
| FY24 | 13.8% | −47% |
| FY23 | 10.8% | −58% |
| FY22 | −6.1% | −80.4% |
| FY21 | −10.7% | −71.9% |
| FY20 | 10.1% | −62.2% |
| FY19 | 24.2% | −46.3% |
| FY18 | 23.6% | −49.6% |
| FY17 | 30.1% | −45.9% |
| FY16 | 26.7% | −36% |
| FY15 | 24.9% | −38.4% |
| FY14 | 5% | −35.5% |
| FY13 | 24.8% | −37.1% |
| FY12 | 49.2% | −29.1% |
| FY11 | 45.9% | −27.9% |